Immune Checkpoint Inhibitor

Spatial comparison of molecular features associated with resistance to pembrolizumab in BCG unresponsive bladder cancer
Khyati Meghani, Noah Frydenlund, Yanni Yu, Bonnie Choy, Joshua J Meeks

Journal for ImmunoTherapy of Cancer Apr 2024, 12 (4) e008571; DOI: 10.1136/jitc-2023-008571
Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy
Bao-Dong Qin, Xiao-Dong Jiao, Ling-Yan Yuan, Ying Wu, Yan Ling, Yuan-Sheng Zang

Journal for ImmunoTherapy of Cancer Apr 2024, 12 (4) e008818; DOI: 10.1136/jitc-2024-008818
Longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC
Nikolaus John, Verena Schlintl, Teresa Sassmann, Jörg Lindenmann, Melanie Fediuk, Robert Wurm, Philipp Douschan, Martin Zacharias, Lipika Kalson, Florian Posch, Gudrun Absenger, Luka Brcic, Philipp J Jost, Angelika Terbuch

Journal for ImmunoTherapy of Cancer Apr 2024, 12 (4) e008592; DOI: 10.1136/jitc-2023-008592
OMA1 competitively binds to HSPA9 to promote mitophagy and activate the cGAS–STING pathway to mediate GBM immune escape
Wen de Zhu, Jin Rao, Li hua Zhang, Ka ming Xue, Lin Li, Jun jun Li, Qian zhi Chen, Rong Fu

Journal for ImmunoTherapy of Cancer Apr 2024, 12 (4) e008718; DOI: 10.1136/jitc-2023-008718
Do galectins serve as soluble ligands for immune checkpoint receptors?
Nicolas I Torres, Federico G Baudou, Marco A Scheidegger, Tomás Dalotto-Moreno, Gabriel A Rabinovich

Journal for ImmunoTherapy of Cancer Apr 2024, 12 (4) e008984; DOI: 10.1136/jitc-2024-008984
Combination of oligo-fractionated irradiation with nivolumab can induce immune modulation in gastric cancer
Kosaku Mimura, Takashi Ogata, Phuong H D Nguyen, Souvick Roy, Hassen Kared, Yate-Ching Yuan, Michael Fehlings, Yuya Yoshimoto, Daisaku Yoshida, Shotaro Nakajima, Hisashi Sato, Nozomu Machida, Takanobu Yamada, Yohei Watanabe, Tomoaki Tamaki, Hirohito Fujikawa, Yasuhiro Inokuchi, Suguru Hayase, Hiroyuki Hanayama, Zenichiro Saze, Hiroyuki Katoh, Fumiaki Takahashi, Takashi Oshima, Ajay Goel, Alessandra Nardin, Yoshiyuki Suzuki, Koji Kono

Journal for ImmunoTherapy of Cancer Jan 2024, 12 (1) e008385; DOI: 10.1136/jitc-2023-008385
Response to Yu and Fuhler et al
Patrick Tiongco Magahis, Steven B Maron, David Faleck, Monika Laszkowska

Journal for ImmunoTherapy of Cancer Jan 2024, 12 (1) e008784; DOI: 10.1136/jitc-2024-008784
Biomarkers for response to TIL therapy: a comprehensive review
Víctor Albarrán Fernández, Pablo Ballestín Martínez, Joachim Stoltenborg Granhøj, Troels Holz Borch, Marco Donia, Inge Marie Svane

Journal for ImmunoTherapy of Cancer Mar 2024, 12 (3) e008640; DOI: 10.1136/jitc-2023-008640
Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06)
Ju Won Kim, Hyo Jin Lee, Ji Yoon Lee, Sook Ryun Park, Yu Jung Kim, In Gyu Hwang, Woo Kyun Bae, Jae Ho Byun, Jung Sun Kim, Eun Joo Kang, Jeeyun Lee, Sang Joon Shin, Won Jin Chang, Eun-Ok Kim, Jason K Sa, Kyong Hwa Park

Journal for ImmunoTherapy of Cancer Mar 2024, 12 (3) e008638; DOI: 10.1136/jitc-2023-008638
Mefloquine enhances the efficacy of anti-PD-1 immunotherapy via IFN-γ-STAT1-IRF1-LPCAT3-induced ferroptosis in tumors
Qian Tao, Nian Liu, Jie Wu, Jing Chen, Xiang Chen, Cong Peng

Journal for ImmunoTherapy of Cancer Mar 2024, 12 (3) e008554; DOI: 10.1136/jitc-2023-008554

Main menu

Immune Checkpoint Inhibitor

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Immune Checkpoint Inhibitor

Pages